The expression of the antiapoptotic (BCL2), protein kinase C (PKC-α), and platelet-derived growth factor receptor (PDGFR-α) pathways was found, which suggests potential targets for mesenchymal chondrosarcoma therapy.[20] The majority of chondrosarcomas grow slowly and have good prognoses after adequate surgery. The gene discussed is PDGFRA; the disease is mesenchymal chondrosarcoma.